-
Telemedicine Allows for First-of-its-Kind Trial Administering Subcutaneous Immunotherapy at Home
17 May 2024 15:47 GMT
… eligible for clinical trial participation.”
The trial will be the … There are some medications such as rituximab [Rituxan] that when given … a number of other drugs that become available as … at-home cancer treatment. News release. Keck Medicine of USC. March …
-
Baby Boomers’ 14 Least Favorite Drug Brands: Ranked
08 May 2024 20:47 GMT
… the success of pharmaceutical companies. If a company’s drugs are unpopular … boomers will rely on their medication and treatments at some point.
10 … .
8. Rituxan
Source: Anut21ng / iStock via Getty Images
This drug is …
-
Calquence delays disease progression as first-line treatment for mantle cell lymphoma
03 May 2024 19:56 GMT
… trial assessed the efficacy and safety of bendamustine and rituximab (Rituxan … a day, on 28-day treatment cycles, plus bendamustine on … and co-director of clinical trials at The University of … be presented at an upcoming medical conference, according to the …
-
US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira®
01 May 2024 14:33 GMT
… injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet … pus.
Call your doctor or get medical care right away … of prescription drugs to the FDA. Visit www.fda.gov… affiliated with Boehringer Ingelheim Pharmaceuticals, Inc.
MPR-US …
-
Rituxan for the Treatment of Non-Hodgkin’s Lymphoma, US
23 Apr 2024 17:29 GMT
… drug under the skin.
Rituxan was developed by Biogen Idec, a biotechnology … Pharmaceutical. In Roche’s pipeline, Rituxan is the second largest-selling drug … trial.
The FDA approved Rituxan as a maintenance treatment … trials on Rituxan
The FDA approved Rituxan …
-
Pirtobrutinib and BTK Inhibitors in the CLL Treatment Landscape
17 Apr 2024 16:38 GMT
… cyclophosphamide, rituximab [Rituxan; Genentech]) for the treatment backbone. Results … RESONATE-2 (NCT01722487) trials. These latter studies … University of Washington Medicine in Seattle, Washington … from the pharmaceutical to the clinical. Drug Des Devel …
-
STARGLO Trial Meets OS End Point With Glofitamab in Relapsed/Refractory DLBCL
15 Apr 2024 17:10 GMT
… in the phase 3 STARGLO trial (NCT04408638) assessing glofitamab ( … was compared with rituximab (Rituxan) plus gemcitabine and oxaliplatin. … of treatment,” Levi Garraway, MD, PhD, chief medical officer … accelerated approval by the FDA for patients with DLBCL …
-
Roche’s Columvi offers survival benefit in Phase III DLBCL trial
15 Apr 2024 14:14 GMT
… against MabThera/Rituxan (rituximab) with GemOx.
The trial participants had received … medicines.
Columvi has received accelerated approval from the US Food and Drug … treatment shortly after diagnosis.
Roche Global Product Development head and chief medical …
-
Roche reports survival data for new dual-acting lymphoma drug
15 Apr 2024 17:24 GMT
… medical meeting, the company said.
Columvi is a new type of drug … cancer treatment. In a separate trial, lymphoma patients given the comparative therapy, Rituxan … ’s drug, Epkinly, which has been evaluated across four late-stage trials …
-
Roche eyes earlier treatment nod after Columvi-chemo trial win in 2nd-line lymphoma
15 Apr 2024 16:26 GMT
… antibody drugs and bispecifics, the Roche unit has revealed a trial … Genentech’s fading oncology powerhouse Rituxan in tandem with GemOx.
… of systemic therapy. The FDA green light kicked off a … treatment,” Levi Garraway, M.D., Ph.D., Genentech’s chief medical …